Vocal Biomarkers Market Research Report Information By Type (Frequency, Amplitude, Error Rate, Vocal Rise or Fall Time, Phonation Time, Voice Tremor, Pitch, and Others), By End-User (Hospitals & Clinics, Academic & Research, and Others), By Verticals (Psychiatric Disorders {Depression, Attention Deficit & Disruptive Behavior Disorders, and Others}, Neurological Disorders {Parkinson's Disease (PD), Alzheimer's Disease, Huntington's Disease, and Others}, Respiratory Disorders, Cardiovascular Disorders, Traumatic Brain Injury (TBI), and Other

Global Vocal Biomarkers Market Overview

vocal biomarkers market size was valued at USD 0.58 Billion in 2023. The vocal biomarkers industry is projected to grow from USD 0.681 Billion in 2024 to USD 2.13 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.31% during the forecast period (2024 - 2032). The increasing preponderance of neurological disorders and the increasing psychological and other speech-related diseases, which include Parkinson's disease, attention deficit, depression and cardiovascular disorders, are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Vocal Biomarkers Market Trends

• Technological advancement is driving the market growth

Market CAGR for vocal biomarkers is driven by the rising integration of Artificial Intelligence (AI). Combining speech-based biomarkers with Al and Machine Learning has the possibility to identify a combination of medical disorders, but the technology must grow before it is widely utilized in clinical settings. As top academic institutes, such as Université de Montréal, seek to launch speech as a biomarker for clinical care, artificial intelligence can soon allow doctors to detect and treat ailments, including cancer and depression, based on a patient's voice. The assignment is being led by Olivier Elemento of Weil Cornell Medicine in New York City and Dr. Yael Bensoussan of the University of South Florida, along with six other organizations in the U.S. and four in Canada, with budget from the U.S. National Institutes of Health totaling USD 14 million over 4 years.

Growing research on speech biomarkers is another factor driving market revenue growth. For instance, initial determinations from a joint research and development action on digital health with Genentech, a component of the Roche Group, were delivered by Winterlight Labs Inc., a speech analytics and digital biomarker business. The project explores novel speech-based digital biomarkers to assess cognitive changes utilizing speech recordings from the Tauriel investigation, a Phase 2 trial of the research anti-tau antibody semorinemab in prodromal-to-mild Alzheimer's disease. The primary conclusions were presented at the 2021 Alzheimer's Association International Conference's Neuropsychiatry and Behavioral Neurology Virtual Oral Session.

Growing prevalence of neurological, psychological, and other speech-related diseases, such as attention deficit, cardiovascular diseases, depression, and Parkinson's disease. As per the new United Nations report released, around 1 billion individuals, or nearly one in six of the globe's population, suffer from neurological disorders, including brain injuries, migraine, and neuro infections, as well as conditions such as Alzheimer's and Parkinson's, multiple sclerosis, stroke, and epilepsy. Each year, 6.8 million people die as a result of these conditions. As proofed by the inclusion of mental fitness in the Sustainable Development Goals, there has been increasing recognition of mental health's crucial role in reaching  development goals driving the vocal biomarkers market revenue.

Vocal Biomarkers Market Segment Insights

Vocal Biomarkers Type Insights

The vocal biomarkers market segmentation, based on type, includes frequency, amplitude, error rate, vocal rise or fall time, phonation time, voice tremor, pitch, and others. The frequency segment dominated the market, accounting for 35% of market revenue (0.20 Billion). In developing countries, category growth is driven by its necessity to confirm that each feature, a feature or metric taken from a speech sample, precisely measures the associated features of speech for speech-based biomarkers. However, amplitude is the fastest-growing category, as a Mayo Clinic research team has linked numerous voice characteristics to a history of coronary artery disease.

Vocal Biomarkers End-User Insights

The vocal biomarkers market segmentation, based on end-user, includes hospitals & clinics, academic & research, and others. The hospitals & clinics category generated the most income due to rising hospital patient admission, given the prevalence of cardiovascular diseases like cardiac arrest, which has been pronouncing the demand for vocal biomarkers to detect the ailment. However, academic & research is the fastest-growing category due to rising vocal biomarkers demand from these academic & research centers.

Figure 1 Vocal Biomarkers Market by End-User, 2023 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Vocal Biomarkers Verticals Insights

The vocal biomarkers market segmentation, based on verticals, includes psychiatric disorders {depression, attention deficit & disruptive behavior disorders, and others}, neurological disorders {Parkinson’s disease (PD), Alzheimer’s disease, Huntington’s disease, and others}, respiratory disorders, cardiovascular disorders, traumatic brain injury (TBI), and others. The neurological disorders category generated the most income (70.4%) due to the increasing prevalence of neurological disorders and the improving application of vocal tremors in neurological disorders. However, psychiatric disorders are the fastest-growing category due to rising vocal biomarkers demand for mental disorders.

Vocal Biomarkers Regional Insights

By region, the study delivers market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American vocal biomarkers market will dominate, owing to the use of vocal biomarkers technology in diagnostics and the adoption of it in the cost-effective form to decide whether the patient has to go through more diagnostics will boost the market growth in this region. Further, the US vocal biomarkers market held the largest market share, and the Canadian vocal biomarkers market was the fastest-growing market in the North American region.

Further, the prominent countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 VOCAL BIOMARKERS MARKET SHARE BY REGION 2023 (USD Billion)

Source Primary Research, MRFR Database, Secondary Research,  and Analyst Review

Europe's vocal biomarkers market accounts for the second-largest market share owing to the increasing Research and Development (R&D) activities in developing economies will boost the market growth in this region. Further, the German vocal biomarkers market held the largest market share, and the UK vocal biomarkers market was the fastest-growing market in the European region.

The Asia-Pacific vocal biomarkers market is predicted to increase at the fastest CAGR from 2023 to 2032. This is due to growing mental health disorders, the presence of major players, and technological advances in the region. Moreover, China’s vocal biomarkers market held the largest market share, and the Indian vocal biomarkers market was the fastest-growing market in the Asia-Pacific region.

Vocal Biomarkers Key Market Players & Competitive Insights

Leading market participants are investing heavily in research and development to develop their product lines, which will enable the vocal biomarkers market to grow even more. Market players are also undertaking various strategic movements to develop their footprint, with significant market developments including new product launches, contractual arrangements, mergers and acquisitions, more elevated investments, and collaboration with other institutions. To develop and survive in a more competitive and growing market climate, the vocal biomarkers industry must deliver cost-effective items.

Manufacturing locally to decrease operational expenses is one of the key business tactics manufacturers operate in the vocal biomarkers industry to benefit clients and increase the market sector. Major players in the vocal biomarkers market, including General Mills Inc., Amway, Conagra Brands Inc., Cargill Incorporated, Abbott Laboratories, Kraft Foods Group Inc., and others, are trying to advance market demand by supporting research and development processes.

Mayo Clinic is a not-for-profit medical exercise and medical research community. It delivers comprehensive medical facilities and programs connected to patient care services, clinical services, research and medical education. Mayo delivers specialized medical care with medical branches and centers in most of the key disease types and health disorders. The company conducts active human research investigations and unique human research studies supported by institutional examination of its structures. The organization also operates several medical colleges presenting various residency and fellowship programs. Its other essential facilities include Mayo Florida, Mayo Arizona, Mayo Minnesota, and Mayo Clinic Health System, a network of hospitals and clinics in several conditions. In October 2020, Mayo Clinic declared collaboration with Vocalis Health to research and develop unique voice-based tools for catching, screening, and monitoring patient fitness. This would help the detection of pulmonary hypertension in individuals.

Sonde Health is a digital health company specializing in voice-based biomarkers and AI-driven technology to detect and monitor various health conditions. The company's mission is to revolutionize healthcare by harnessing the power of voice to improve early detection, diagnosis, and treatment of diseases. In October 2021, Sonde Health unveiled Sonde Mental Fitness, a voice-enabled mental health detection and monitoring technology that uses a brief voice sample to evaluate mental well-being. Available as an application programming interface for health systems, employers, and wellness service providers.

Key Companies in the Vocal Biomarkers market include

• Boston Technology Corporation


• Cogito


• ConversationHealth


• IBM


• Winterlight Labs


• GoDaddy, LLC.


• Medical Information Technology, Inc.


• Mayo Foundation for Medical Education and Research (MFMER)


• Sonde Health, Inc.


• Pure Tech

Vocal Biomarkers Industry Developments

March 2021 Sonde Health teamed up with Xavier University Center for Population Health to analyze the effectiveness of the former's vocal biomarker platform as a screening tool for COVID-19 symptoms.

June 2021 Medable's Cancer Moonshot work collaborated with Aural Analytics, which provides clinical-grade voice collecting and analytical instruments to assess remote data gathering and digital biomarkers in cancer patients. The partnership will observe the health of oncology patients using the Medable platform for decentralized trials utilizing Aural Analytics technology. The National Institutes of Health Beau Biden Cancer Moonshot Program was launched five years ago, a seven-year action named in memory of President Joe Biden's late son. Via the 21st Century Cures Act, the action has funded an additional USD 18 billion in cancer research. Moonshot money has invested in 240 research projects across more than 70 initiatives, with Medable obtaining funding in 2018.

Vocal Biomarkers Market Segmentation

Vocal Biomarkers Type Outlook

• Frequency


• Amplitude


• Error Rate


• Vocal Rise Or Fall Time


• Phonation Time


• Voice Tremor


• Pitch


• Others

Vocal Biomarkers Verticals Outlook

• Psychiatric Disorders
  
  
  
  • Depression
  
  
  • Attention Deficit & Disruptive Behavior Disorders
  
  
  • Others
  
  
  
  


• Neurological Disorders
  
  
  
  • Parkinson's Disease (PD)
  
  
  • Alzheimer's Disease
  
  
  • Huntington's Disease
  
  
  • Others
  
  
  
  


• Respiratory Disorders


• Cardiovascular Disorders


• Traumatic Brain Injury (TBI)


• Others

Vocal Biomarkers End-User Outlook

• Hospitals & Clinics


• Academic & Research


• Others

Vocal Biomarkers Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America